Your activity: 6 p.v.
Why UpToDate?
What's New
Patient Education
Calculators
Drug interactions
Subscribe
Log In
< Back
Uptodate Reference Title
Go To Link
Close
TP53 mutations and treatment outcome in CLL
TP53 mutations and treatment outcome in CLL
Kaplan-Meier estimates of progression-free survival (A) and overall survival (B) according to TP53 mutation status in patients with chronic lymphocytic leukemia (CLL) initially treated with fludarabine, cyclophosphamide, and rituximab.
FCR: fludarabine, cyclophosphamide, and rituximab; PFS: progression-free survival; OS: overall survival;
TP53
WT
: wild-type
TP53
;
TP53
mut
: mutant
TP53.
This research was originally published in Blood. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014; 123:3247. Copyright © 2014 American Society of Hematology.
Graphic 108430 Version 1.0